1 – 31 of 31
- show: 250
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2024
-
Mark
Large differencies in age-specific survival in multiple myeloma in the nordic countries
(
- Contribution to journal › Debate/Note/Editorial
-
Mark
Age-specific survival in acute myeloid leukemia in the Nordic countries through a half century
(
- Contribution to journal › Debate/Note/Editorial
-
Mark
Genome-wide CRISPR/Cas9 screen identifies regulators of BCMA expression on multiple myeloma cells
(
- Contribution to journal › Debate/Note/Editorial
-
Mark
Haplotype analysis identifies functional elements in monoclonal gammopathy of unknown significance
(
- Contribution to journal › Article
- 2023
-
Mark
PLK1 as a cooperating partner for BCL2-mediated antiapoptotic program in leukemia
(
- Contribution to journal › Article
- 2022
-
Mark
Validation and functional characterization of GWAS-identified variants for chronic lymphocytic leukemia : a CRuCIAL study
(
- Contribution to journal › Letter
-
Mark
Genome-wide meta-analysis of monoclonal gammopathy of undetermined significance (MGUS) identifies risk loci impacting IRF-6
(
- Contribution to journal › Letter
- 2021
-
Mark
Germline variants at SOHLH2 influence multiple myeloma risk
(
- Contribution to journal › Article
-
Mark
Incidence of relapsed/refractory diffuse large B-cell lymphoma (DLBCL) including CNS relapse in a population-based cohort of 4243 patients in Sweden
(
- Contribution to journal › Article
-
Mark
Characteristics and outcome of acute myeloid leukemia with uncommon retinoic acid receptor-alpha (RARA) fusion variants
(
- Contribution to journal › Letter
-
Mark
Characterization of rare germline variants in familial multiple myeloma
(
- Contribution to journal › Letter
- 2020
-
Mark
Parental origin of monosomic chromosomes in near-haploid acute lymphoblastic leukemia
(
- Contribution to journal › Letter
-
Mark
International Myeloma Working Group risk stratification model for smoldering multiple myeloma (SMM)
(
- Contribution to journal › Article
-
Mark
The CCND1 c.870G risk allele is enriched in individuals of African ancestry with plasma cell dyscrasias
(
- Contribution to journal › Letter
- 2019
-
Mark
Types of second primary cancers influence survival in chronic lymphocytic and hairy cell leukemia patients
(
- Contribution to journal › Letter
-
Mark
The ALK inhibitor AZD3463 effectively inhibits growth of sorafenib-resistant acute myeloid leukemia
(
- Contribution to journal › Letter
-
Mark
Sequence variation at the MTHFD1L-AKAP12 and FOPNL loci does not influence multiple myeloma survival in Sweden
(
- Contribution to journal › Letter
- 2018
-
Mark
Genetic correlation between multiple myeloma and chronic lymphocytic leukaemia provides evidence for shared aetiology
(
- Contribution to journal › Article
-
Mark
Clinical predictors of long-term survival in newly diagnosed transplant eligible multiple myeloma - an IMWG Research Project
(
- Contribution to journal › Article
-
Mark
Multiple myeloma : family history and mortality in second primary cancers
(
- Contribution to journal › Letter
-
Mark
Differences in genomic abnormalities among African individuals with monoclonal gammopathies using calculated ancestry
(
- Contribution to journal › Article
- 2017
-
Mark
Assessing the effect of obesity-related traits on multiple myeloma using a Mendelian randomisation approach
(
- Contribution to journal › Letter
-
Mark
Familial associations of lymphoma and myeloma with autoimmune diseases
(
- Contribution to journal › Article
- 2016
-
Mark
An open-label phase I dose-finding study of APR-246 in hematological malignancies
(
- Contribution to journal › Article
-
Mark
Search for familial clustering of cancer in monoclonal gammopathy of unknown significance
(
- Contribution to journal › Letter
-
Mark
Plasma immunoprofiling of patients with high-risk diffuse large B-cell lymphoma : a Nordic Lymphoma Group study
(
- Contribution to journal › Article
-
Mark
Splanchnic vein thrombosis in myeloproliferative neoplasms : Risk factors for recurrences in a cohort of 181 patients
(
- Contribution to journal › Article
- 2014
-
Mark
Modeling chronic myeloid leukemia in immunodeficient mice reveals expansion of aberrant mast cells and accumulation of pre-B cells.
(
- Contribution to journal › Article
-
Mark
Bone morphogenetic protein-9 suppresses growth of myeloma cells by signaling through ALK2 but is inhibited by endoglin.
(
- Contribution to journal › Article
-
Mark
Incidence and prognostic significance of karyotypic subgroups in older patients with acute myeloid leukemia: the Swedish population-based experience.
(
- Contribution to journal › Article
-
Mark
Limited clinical efficacy of azacitidine in transfusion-dependent, growth factor-resistant, low- and Int-1-risk MDS : Results from the nordic NMDSG08A phase II trial
(
- Contribution to journal › Article